- Home
- LANC vs BBIO Comparison
LANC vs BBIO Comparison
Compare LANC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANC
- BBIO
- Stock Information
- Founded
- LANC 1961
- BBIO 2015
- Country
- LANC United States
- BBIO United States
- Employees
- LANC N/A
- BBIO N/A
- Industry
- LANC Packaged Foods
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LANC Consumer Staples
- BBIO Health Care
- Exchange
- LANC Nasdaq
- BBIO Nasdaq
- Market Cap
- LANC N/A
- BBIO 8.0B
- IPO Year
- LANC N/A
- BBIO 2019
- Fundamental
- Price
- LANC $180.02
- BBIO $45.60
- Analyst Decision
- LANC Buy
- BBIO Strong Buy
- Analyst Count
- LANC 4
- BBIO 14
- Target Price
- LANC $209.67
- BBIO $58.85
- AVG Volume (30 Days)
- LANC 166.2K
- BBIO 3.3M
- Earning Date
- LANC 08-21-2025
- BBIO 07-31-2025
- Dividend Yield
- LANC 2.20%
- BBIO N/A
- EPS Growth
- LANC 27.36
- BBIO N/A
- EPS
- LANC 6.15
- BBIO N/A
- Revenue
- LANC $1,886,520,000.00
- BBIO $127,415,000.00
- Revenue This Year
- LANC $3.16
- BBIO $102.05
- Revenue Next Year
- LANC $2.33
- BBIO $54.69
- P/E Ratio
- LANC $28.11
- BBIO N/A
- Revenue Growth
- LANC 0.69
- BBIO N/A
- 52 Week Low
- LANC $156.14
- BBIO $21.72
- 52 Week High
- LANC $202.63
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- LANC 65.92
- BBIO 66.67
- Support Level
- LANC $165.16
- BBIO $41.80
- Resistance Level
- LANC $184.36
- BBIO $45.48
- Average True Range (ATR)
- LANC 4.35
- BBIO 1.57
- MACD
- LANC 1.40
- BBIO -0.01
- Stochastic Oscillator
- LANC 77.42
- BBIO 78.42
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.